These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9389932)

  • 1. Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
    Moreland N; Finlay GJ; Dragunow M; Holdaway KM; Baguley BC
    Eur J Cancer; 1997 Sep; 33(10):1668-76. PubMed ID: 9389932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.
    Baguley BC; Leteurtre F; Riou JF; Finlay GJ; Pommier Y
    Eur J Cancer; 1997 Feb; 33(2):272-9. PubMed ID: 9135499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells.
    Finlay GJ; Holdaway KM; Baguley BC
    Cancer Chemother Pharmacol; 1994; 34(2):159-65. PubMed ID: 8194167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
    Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
    Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.
    Giuliano M; Lauricella M; Vassallo E; Carabillò M; Vento R; Tesoriere G
    Invest Ophthalmol Vis Sci; 1998 Jul; 39(8):1300-11. PubMed ID: 9660477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A; Finlay GJ; Baguley BC
    Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
    Leontiou C; Lakey JH; Austin CA
    Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of p53 induces M-phase retardation following G2 DNA damage checkpoint abrogation.
    Minemoto Y; Uchida S; Ohtsubo M; Shimura M; Sasagawa T; Hirata M; Nakagama H; Ishizaka Y; Yamashita K
    Arch Biochem Biophys; 2003 Apr; 412(1):13-9. PubMed ID: 12646262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 protein accumulation in addition to the transactivation activity is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin.
    Jaks V; Jõers A; Kristjuhan A; Maimets T
    Oncogene; 2001 Mar; 20(10):1212-9. PubMed ID: 11313865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
    Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
    Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
    D'Arpa P; Beardmore C; Liu LF
    Cancer Res; 1990 Nov; 50(21):6919-24. PubMed ID: 1698546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokinetic differences in the action of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide as compared with that of amsacrine and doxorubicin.
    Haldane A; Holdaway KM; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1993; 32(6):463-70. PubMed ID: 8258195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic action and cell cycle effects of ALGA, a peptidic derivative of the antileukemic drug amsacrine.
    Collyn-d'Hooghe M; Bernier JL; Henichart JP
    Cancer Biochem Biophys; 1987 Sep; 9(3):257-64. PubMed ID: 3435897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout cells to antitumor triazoloacridone C-1305 is associated with permanent G2 cell cycle arrest.
    Wesierska-Gadek J; Schloffer D; Gueorguieva M; Uhl M; Skladanowski A
    Cancer Res; 2004 Jul; 64(13):4487-97. PubMed ID: 15231658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
    Holm C; Covey JM; Kerrigan D; Pommier Y
    Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
    Del Bino G; Darzynkiewicz Z
    Cancer Res; 1991 Feb; 51(4):1165-9. PubMed ID: 1997159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of fluorescence in situ hybridisation to study the relationship between cytotoxicity, chromosome aberrations, and changes in chromosome number after treatment with the topoisomerase II inhibitor amsacrine.
    Ferguson LR; Whiteside G; Holdaway KM; Baguley BC
    Environ Mol Mutagen; 1996; 27(4):255-62. PubMed ID: 8665870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.